You're using an outdated browser. This website will not display correctly and some features will not work.
Learn more about the browsers we support for a faster and safer online experience.

R.R.O. 1990, Reg. 935: GENERAL

under Drug Interchangeability and Dispensing Fee Act, R.S.O. 1990, c. P.23

Skip to content
Versions
current March 7, 2024 (e-Laws currency date)
April 6, 2020 March 6, 2024
January 1, 2020 April 5, 2020
December 13, 2019 December 31, 2019
October 1, 2016 December 12, 2019
September 23, 2016 September 30, 2016
October 1, 2015 September 22, 2016
September 18, 2015 September 30, 2015
April 1, 2013 September 17, 2015
January 23, 2013 March 31, 2013
April 1, 2012 January 22, 2013
April 1, 2011 March 31, 2012
July 1, 2010 March 31, 2011
June 7, 2010 June 30, 2010
October 16, 2008 June 6, 2010
July 12, 2007 October 15, 2008
July 4, 2007 July 11, 2007
April 1, 2007 July 3, 2007
December 14, 2006 March 31, 2007
October 1, 2006 December 13, 2006
September 28, 2006 September 30, 2006
September 6, 2006 September 27, 2006
August 24, 2006 September 5, 2006
August 22, 2006 August 23, 2006
August 10, 2006 August 21, 2006
July 17, 2006 August 9, 2006
July 5, 2006 July 16, 2006
June 15, 2006 July 4, 2006
June 14, 2006 June 14, 2006
May 31, 2006 June 13, 2006
May 19, 2006 May 30, 2006
May 5, 2006 May 18, 2006
April 19, 2006 May 4, 2006
April 4, 2006 April 18, 2006
March 21, 2006 April 3, 2006
March 3, 2006 March 20, 2006
March 1, 2006 March 2, 2006
February 15, 2006 February 28, 2006
January 24, 2006 February 14, 2006
January 12, 2006 January 23, 2006
January 10, 2006 January 11, 2006
December 9, 2005 January 9, 2006
December 6, 2005 December 8, 2005
November 22, 2005 December 5, 2005
November 8, 2005 November 21, 2005
October 25, 2005 November 7, 2005
October 6, 2005 October 24, 2005
September 27, 2005 October 5, 2005
September 22, 2005 September 26, 2005
September 16, 2005 September 21, 2005
September 1, 2005 September 15, 2005
August 30, 2005 August 31, 2005
August 19, 2005 August 29, 2005
August 5, 2005 August 18, 2005
July 14, 2005 August 4, 2005
June 29, 2005 July 13, 2005
June 13, 2005 June 28, 2005
May 30, 2005 June 12, 2005
May 25, 2005 May 29, 2005
May 2, 2005 May 24, 2005
April 28, 2005 May 1, 2005
March 31, 2005 April 27, 2005
March 23, 2005 March 30, 2005
February 24, 2005 March 22, 2005
February 22, 2005 February 23, 2005
February 16, 2005 February 21, 2005
February 3, 2005 February 15, 2005
January 25, 2005 February 2, 2005
January 21, 2005 January 24, 2005
December 21, 2004 January 20, 2005
December 9, 2004 December 20, 2004
November 16, 2004 December 8, 2004
November 10, 2004 November 15, 2004
November 4, 2004 November 9, 2004
October 14, 2004 November 3, 2004
October 8, 2004 October 13, 2004
October 6, 2004 October 7, 2004
September 14, 2004 October 5, 2004
September 3, 2004 September 13, 2004
August 11, 2004 September 2, 2004
August 4, 2004 August 10, 2004
July 20, 2004 August 3, 2004
June 28, 2004 July 19, 2004
April 6, 2004 June 27, 2004
March 12, 2004 April 5, 2004
September 4, 2003 March 11, 2004
83 more

Drug Interchangeability and Dispensing Fee Act
Loi sur l’interchangeabilité des médicaments et les honoraires de préparation

R.R.O. 1990, REGULATION 935

GENERAl

Historical version for the period October 1, 2015 to September 22, 2016.

Last amendment: O. Reg. 285/15.

This Regulation is made in English only.

1. (1) In this Regulation,

“original product” means the original source of a drug product in a particular strength and dosage form;

“production size lot” means the amount of finished product that is made from the minimum quantity of raw materials specified in a formula that can be processed using full sized production equipment into a dosage form that meets the specifications for the finished product.

R.R.O. 1990, Reg. 935, s. 1; O. Reg. 235/92, s. 1; O. Reg. 460/92, s. 1; O. Reg. 757/92, s. 1; O. Reg. 101/93, s. 1; O. Reg. 318/93, s. 1 (1); O. Reg. 453/93, s. 1; O. Reg. 524/93, s. 1; O. Reg. 526/93, s. 1; O. Reg. 735/93, s. 1; O. Reg. 49/94, s. 1 (1); O. Reg. 108/94, s. 1; O. Reg. 452/94, s. 1 (1); O. Reg. 615/94, s. 1; O. Reg. 755/94, s. 1 (1); O. Reg. 792/94, s. 1; O. Reg. 40/95, s. 1; O. Reg. 305/95, s. 1; O. Reg. 371/95, s. 1; O. Reg. 479/95, s. 1 (1); O. Reg. 177/96, s. 1; O. Reg. 337/96, s. 1; O. Reg. 376/96, s. 1; O. Reg. 509/96, s. 1 (1); O. Reg. 28/97 s. 1; O. Reg. 111/97, s. 1; O. Reg. 300/97, s. 1; O. Reg. 613/98, s. 1; O. Reg. 73/99, s. 1; O. Reg. 333/99, s. 1; O. Reg. 402/99, s. 1; O. Reg. 587/99, s. 1; O. Reg. 201/00, s. 1 (1); O. Reg. 367/00, s. 1; O. Reg. 583/00, s. 1; O. Reg. 15/01, s. 1; O. Reg. 173/01, s. 1 (1); O. Reg. 359/01, s. 1; O. Reg. 63/02, s. 1; O. Reg. 215/02, s. 1; O. Reg. 394/02, s. 1; O. Reg. 89/03, s. 1; O. Reg. 335/03, s. 1; O. Reg. 59/04, s. 1; O. Reg. 183/04, s. 1; O. Reg. 215/04, s. 1; O. Reg. 277/04, s. 1; O. Reg. 319/04, s. 1; O. Reg. 358/04, s. 1; O. Reg. 378/04, s. 1; O. Reg. 6/05, s. 1; O. Reg. 13/05, s. 1; O. Reg. 35/05, s. 1; O. Reg. 128/05, s. 1; O. Reg. 188/05, s. 1; O. Reg. 190/05, s. 1; O. Reg. 240/05, s. 1; O. Reg. 418/05, s. 1; O. Reg. 458/05, s. 1; O. Reg. 485/05, s. 1 (1); O. Reg. 488/05, s. 1; O. Reg. 500/05, s. 1 (1); O. Reg. 545/05, s. 1; O. Reg. 54/06, ss. 1 (1); O. Reg. 203/06, s. 1; O. Reg. 458/06, s. 1 (1-3).

(1.1) Revoked:  O. Reg. 54/06, s. 1 (2).

(1.2), (1.3) Revoked:  O. Reg. 458/06, s. 1 (4).

(2) For the purposes of subsection 1 (2) of the Act,

“therapeutic substitution” means the substitution of a drug that contains chemically different active ingredients that are considered to be therapeutically equivalent, without authorization from a person authorized to prescribe drugs within the scope of his or her practice of a health profession.  O. Reg. 458/06, s. 1 (4).

(3) Revoked:  O. Reg. 221/10, s. 1.

(4) Revoked:  O. Reg. 458/06, s. 1 (4).

(5) Revoked:  O. Reg. 485/05, s. 1 (2).

(6) Revoked:  O. Reg. 458/06, s. 1 (4).

2. (1) Revoked: O. Reg. 221/10, s. 2 (6).

(1.1) Revoked: O. Reg. 221/10, s. 2 (6).

(2) Revoked: O. Reg. 221/10, s. 2 (6).

(3) For the purposes of section 12.1 of the Act, a “rebate” does not include the value of a benefit that is provided in accordance with ordinary commercial terms that meet all of the following conditions:

1. The benefit is provided in the ordinary course of business in the supply chain system of interchangeable products between any of a manufacturer, a wholesaler, an operator of a pharmacy or a company that owns, operates or franchises pharmacies.

2. The value of the benefit is set out in a written agreement between any of a manufacturer, a wholesaler, an operator of a pharmacy and a company that owns, operates or franchises pharmacies.

3. The benefit relates to an ordinary commercial relationship that is any of the following:

i. A prompt payment discount.

ii. A volume discount.

iii. A distribution service fee.

4. In the case of product that is not supplied to an eligible person under the Ontario Drug Benefit Act, the total value of any benefits does not exceed 10 per cent of the value of the interchangeable products based on the number of units dispensed by a pharmacy at each product’s price, which shall not exceed the price the product may be sold at under subsection 8 (1) where that subsection applies to the product.

5. A person who receives the benefit reports to the executive officer, if required by the executive officer to do so, the net selling price of the drug products representing the price of the product less the value of the benefits received.  O. Reg. 221/10, s. 2 (5).

3. Revoked:  O. Reg. 458/06, s. 2.

4. Revoked:  O. Reg. 204/96, s. 1.

5. A person may charge more than the person’s usual and customary dispensing fee for a product that is supplied pursuant to a prescription if the person explains why a fee in excess of the usual and customary fee is being charged prior to the dispensing of the prescription and the charging of the additional fee is not an act of professional misconduct under section 1 of Ontario Regulation 681/93 made under the Pharmacy Act, 1991.  R.R.O. 1990, Reg. 935, s. 5; O. Reg. 377/94, s. 1.

6. (1) It is a condition for each strength and dosage form of a drug product to be designated as interchangeable with other products that the manufacturer of the drug product submit to the executive officer,

(a) evidence that Health Canada has approved the product for sale in Canada, a copy of the product’s drug notification form issued by Health Canada and, subject to subsection (2), a copy of the product monograph approved by Health Canada;

(b) a letter authorizing the executive officer to gain access to all information with respect to the product in the possession of Health Canada, the Patented Medicine Prices Review Board established under section 91 of the Patent Act (Canada), the government of any province or territory in Canada or the Canadian Agency for Drugs and Technologies in Health and authorizing the executive officer to disclose any information with respect to the product in the possession of the Ministry to Health Canada, the Patented Medicine Prices Review Board, the government of a province or territory in Canada or the Canadian Agency for Drugs and Technologies in Health;

(c) documentation disclosing the product’s master formulation;

(d) the proposed drug benefit price of the product, where it is proposed that the product be designated as a listed drug product under the Ontario Drug Benefit Act, and a proposed manufacturer’s list price where it is not proposed that the product be so designated;

(d.1) Revoked:  O. Reg. 496/00, s. 1 (4).

(e) evidence that the manufacturer is able to supply the product at the proposed drug benefit price in a quantity sufficient to meet the anticipated demand for the product where it is proposed that the product be designated as a listed drug product under the Ontario Drug Benefit Act;

(f) certification in writing that no rebate as defined in subsection 12.1 (14) of the Act has been provided to a person listed in subsection 12.1 (1) of the Act with respect to the product contrary to the Act since Health Canada approved the product for sale in Canada;

(g) Revoked:  O. Reg. 496/00, s. 1 (5).

(h) comparative bioavailability studies on humans, comparative clinical studies on humans, or both, or other in vivo studies that will show the interchangeability of the product with the original product.

(i) Revoked:  O. Reg. 496/00, s. 1 (6).

O. Reg. 18/96, s. 1; O. Reg. 204/96, s. 2; O. Reg. 28/97, s. 2 (1, 2); O. Reg. 496/00, s. 1 (1-6); O. Reg. 337/03, s. 1 (1); O. Reg. 644/05, s. 2; O. Reg. 458/06, s. 3 (1-3); O. Reg. 321/07, s. 1 (1).

(2) If Health Canada has not approved a product monograph for a drug product, the manufacturer of the product may, instead of submitting a copy of the product monograph as required under clause (1) (a), submit to the executive officer the following information:

1. Pharmaceutical information.

2. Information with respect to the product’s clinical pharmacology.

3. Information as to the product’s indications and clinical use.

4. A list of any contra-indications, warnings or precautions in the use of the product and of possible adverse reactions to its use.

5. A list of symptoms of an overdose of the product and information as to the treatment of an overdose.

6. Information with respect to the dosage and administration of the product.

7. Information regarding the availability of dosage forms for each strength of the product marketed in Canada.  O. Reg. 18/96, s. 1; O. Reg. 496/00, s. 1 (7); O. Reg. 458/06, s. 3 (4).

(3) Clauses (1) (c) and (h) do not apply to the manufacturer of a drug product if the dosage form, strength, formula and manufacturing process of the product and the testing standards for both the raw materials of the product and the finished product are identical to those of the product with which it seeks to be designated as interchangeable.  O. Reg. 18/96, s. 1; O. Reg. 496/00, s. 1 (8).

(4) A manufacturer may satisfy the condition set out in clause (1) (h) for a strength of a drug product by submitting the evidence referred to in clause (1) (h) for another strength of the same dosage form of the drug product if that information is sufficient for the purposes of evaluating the interchangeability of both the strengths of the dosage form of the product.  O. Reg. 18/96, s. 1.

(5) Clause (1) (h) does not apply with respect to a drug product that is pharmaceutically equivalent to the original product, demonstrates the same physicochemical properties of the original product, is the same dosage form, packaging format and strength as the original product and is one of the following:

1. A parenteral aqueous solution, or a powder for reconstitution into an aqueous solution, that may be administered in an intravenous, intramuscular, subcutaneous or intrathecal fashion and that is in the same solvent and in the same concentration as the original product.

2. An oral solution, elixir, syrup or other similar solubilized form in the same concentration as the original product and which contains no ingredient that will affect the bioavailability of the active ingredient.

3. An ophthalmic, otic, nasal, rectal, vaginal or inhaled solution that is topical and aqueous.  O. Reg. 18/96, s. 1; O. Reg. 496/00, s. 1 (9); O. Reg. 285/15, s. 1 (1).

(5.1) For the purposes of subsection (5), if a drug product has been designated by Health Canada on or after February 15, 2005 as equivalent to the original product or to another listed interchangeable product with which it would be designated as interchangeable, the drug product shall be deemed to be pharmaceutically equivalent to the original product and to demonstrate the same physicochemical properties of the original product.  O. Reg. 485/05, s. 2 (1); O. Reg. 321/07, s. 1 (2).

(6) Clause (1) (c) does not apply with respect to a product that has been designated by Health Canada as equivalent to the original product or to another listed interchangeable product with which it would be designated as interchangeable unless the product is described in subsection (5).  O. Reg. 485/05, s. 2 (2).

(7) Clause (1) (h) does not apply to a product that is a solid oral dosage form for systemic effect and that has been designated by Health Canada as equivalent to the original product or to another listed interchangeable product with which it would be designated as interchangeable.  O. Reg. 485/05, s. 2 (2).

(7.1) Clause (1) (h) does not apply to a dermatological product that contains one or more glucocorticoids as the only active ingredient or ingredients and that has been designated by Health Canada as equivalent to the original product or to another listed interchangeable product with which it would be designated as interchangeable. O. Reg. 285/15, s. 1 (2).

(7.2) Clause (1) (h) does not apply to a product with a transdermal route of administration for systemic effect that has been designated by Health Canada as equivalent to the original product or to another listed interchangeable product with which it would be designated as interchangeable. O. Reg. 285/15, s. 1 (2).

(8) A strength and dosage form of a drug product that contains oxycodone as the only active ingredient and that is a long-acting product that has been formulated in a solid dosage form for oral administration shall not be designated as interchangeable unless the following conditions are met:

1. There must be evidence satisfactory to the executive officer that the drug product exhibits one or more physiochemical properties that, when compared to drugs without the property or properties, make the drug product,

i. significantly more difficult to alter, break, crush, chew, dissolve or otherwise manipulate in such a way that it could be misused, abused or put to an intended use that is different than the use for which it is prescribed, or

ii. significantly less effective and less likely to be misused, abused or put to an intended use that is different than the use for which it is prescribed, if the product is altered, broken, crushed, chewed, dissolved or otherwise manipulated.

2. The evidence referred to in paragraph 1 must be demonstrated by,

i. in vitro testing,

ii. in vivo testing,

iii. another form of testing of equivalent reliability, or

iv. a combination of any of the forms of testing mentioned in subparagraphs i to iii. O. Reg. 21/13, s. 1.

7. Where it is proposed that the strength and dosage form of a product be designated as interchangeable and it is proposed that it also be designated as a listed drug product under the Ontario Drug Benefit Act, an additional condition to be met in order for it to be designated as interchangeable is that the proposed drug benefit price must be no greater than the price permitted under that Act for the strength and dosage form of the product.  O. Reg. 221/10, s. 3.

8. (1) The following conditions must be met in order for a drug product that has been designated as interchangeable to continue to be designated as interchangeable:

1. The manufacturer of the product shall give the executive officer notice of any change made to the product, including a formulation change, and of any change in the ownership of the manufacturer.

2. The product must be authorized for sale under the Food and Drugs Act (Canada).

3. The manufacturer of the product must continue to be able to supply the product at the drug benefit price in a quantity that is sufficient to meet the demand for the product where the product is designated as a listed drug product under the Ontario Drug Benefit Act.

4. If the product is a listed drug product under the Ontario Drug Benefit Act, the manufacturer shall not sell the product at a price higher than the drug benefit price permitted under that Act whether or not the product is supplied for the purposes of that Act.

5. Revoked:  O. Reg. 221/10, s. 4 (3).

5.1, 5.2  Revoked:  O. Reg. 221/10, s. 4 (1).

6. Revoked:  O. Reg. 221/10, s. 4 (3).

7. If the drug product has not been designated as a listed drug product under the Ontario Drug Benefit Act, the manufacturer of the product shall give the executive officer notice of every change in the manufacturer’s list price for the drug product.

8. The manufacturer must not have provided a rebate as defined in subsection 12.1 (14) of the Act to a person listed in subsection 12.1 (1) of the Act with respect to the product contrary to the Act since Health Canada approved the product for sale in Canada.

9. If required by the executive officer, the manufacturer of a product that has been designated as interchangeable shall inform the executive officer of the price that the manufacturer receives for the product, net of the value of any ordinary commercial terms.  O. Reg. 28/97, s. 3; O. Reg. 458/06, s. 5 (1-4); O. Reg. 558/06, s. 3 (1, 2); O. Reg. 321/07, s. 2 (1-4); O. Reg. 354/08, s. 2 (1-3); O. Reg. 221/10, s. 4 (1-4); O. Reg. 221/10, s. 4 (5).

(2) For greater certainty, the conditions set out in subsection (1) apply whether the designation of the product as an interchangeable product took place before, on or after July 1, 2010.  O. Reg. 458/06, s. 5 (5); O. Reg. 221/10, s. 4 (6).

(3) Revoked:  O. Reg. 221/10, s. 4 (7).

(4) Revoked:  O. Reg. 221/10, s. 4 (9).

9. (1) A product that is a private label product shall not be designated as interchangeable.  O. Reg. 221/10, s. 5.

(2) In this section,

“private label product” includes a drug product in respect of which,

(a) the manufacturer applying for the designation of the product as a listed drug product does not directly fabricate the product itself, and

(i) is not controlled by a person that directly fabricates the product, or

(ii) does not control the person that directly fabricates the product, and

(b) either,

(i) the manufacturer does not have an arm’s-length relationship with a wholesaler, an operator of a pharmacy or a company that owns, operates or franchises pharmacies, or

(ii) the product is to be supplied under a marketing arrangement associating the product with a wholesaler or one or more operators of pharmacies or companies that own, operate or franchise pharmacies.  O. Reg. 221/10, s. 5.

Schedule 1 Revoked: O. Reg. 221/10, s. 6 (3).